Kubota K, Yamada S, Ishiwata K, Ito M, Fujiwara T, Fukuda H, Tada M, Ido T
Department of Radiology and Nuclear Medicine, Tohoku University, Sendai, Japan.
Eur J Nucl Med. 1993 Jun;20(6):495-501. doi: 10.1007/BF00175162.
We carried out a study to evaluate treatment response and residual mass in lung cancer with positron emission tomography (PET), using L-[methyl-11C]methionine (MET). MET tumour uptake and tumour volume measured by computed tomography (CT) before and within 2 weeks after radiotherapy or chemoradiotherapy were compared in 43 studies of 21 patients. Ten patients with local control (no recurrence) of tumour showed a larger decrease in MET uptake (65.2% +/- 12.2%) than in tumour volume (50.8% +/- 9.6%, P < 0.01). Five patients with early recurrence (from 1 to 4 months) showed smaller decreases in both MET uptake (22.2% +/- 13.5%) and tumour volume (28.6% +/- 20.0%) than those in the no-recurrence group (P < 0.01). Four patients with late recurrence (after 11 months or more) showed a similar decrease to the no-recurrence group in MET uptake (72.8% +/- 14.8%) but little change in tumour volume (18.5% +/- 19.0%), the latter result corresponding to that in the early-recurrence group. Using tumour volume only, the no-recurrence group was differentiated from both the early- and the late-recurrence group (P < 0.01), but the early-recurrence group was not differentiated from the late-recurrence group. Using the MET uptake data, the early-recurrence group was clearly distinguished from the late-recurrence group (P < 0.01), but the late-recurrence group was indistinguishable from the no-recurrence group. CT was useful in distinguishing the no-recurrence group from the groups in which there was ultimate recurrence, whether early or late. When a residual mass is seen on CT, PET seems to be helpful in evaluating tumour viability.
我们开展了一项研究，使用L-[甲基-¹¹C]蛋氨酸（MET）通过正电子发射断层扫描（PET）评估肺癌的治疗反应和残留肿块。在对21例患者的43项研究中，比较了放疗或放化疗前及放疗或放化疗后2周内通过计算机断层扫描（CT）测量的MET肿瘤摄取和肿瘤体积。10例肿瘤局部控制（无复发）的患者MET摄取的下降幅度（65.2%±12.2%）大于肿瘤体积的下降幅度（50.8%±9.6%，P<0.01）。5例早期复发（1至4个月）的患者MET摄取（22.2%±13.5%）和肿瘤体积（28.6%±20.0%）的下降幅度均小于无复发组（P<0.01）。4例晚期复发（11个月或更长时间后）的患者MET摄取的下降幅度（72.8%±14.8%）与无复发组相似，但肿瘤体积变化不大（18.5%±19.0%），后一结果与早期复发组的结果一致。仅使用肿瘤体积，无复发组与早期和晚期复发组均可区分（P<0.01），但早期复发组与晚期复发组无法区分。使用MET摄取数据，早期复发组与晚期复发组可明显区分（P<0.01），但晚期复发组与无复发组无法区分。CT有助于将无复发组与最终复发的组（无论早期还是晚期）区分开来。当CT上看到残留肿块时，PET似乎有助于评估肿瘤的存活情况。
